Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.65 |
| ▸ | DRD4 | P21917 | 6/20 | 0.65 |
| ▸ | DRD3 | P35462 | 6/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.54 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9011831 | 1.00 | DRD2 (0.65) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL3805304 | 0.97 | DRD2 (0.68) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL5929468 | 0.92 | DRD2 (0.68) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL12122194 | 0.91 | NR5A1 (0.68) | DRD2DRD4DRD3GAANR5A1 | |
| SCHEMBL22207170 | 0.91 | NR5A1 (0.68) | DRD2DRD4DRD3GAANR5A1 | |
| SCHEMBL22207285 | 0.91 | NR5A1 (0.68) | DRD2DRD4DRD3GAANR5A1 | |
| SCHEMBL20530526 | 0.91 | DRD2 (0.57) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL21167283 | 0.91 | NR5A1 (0.68) | DRD2DRD4DRD3GAANR5A1 | |
| SCHEMBL13991627 | 0.91 | NR5A1 (0.68) | DRD2DRD4DRD3GAANR5A1 | |
| SCHEMBL7761726 | 0.91 | NR5A1 (0.68) | DRD2DRD4DRD3GAANR5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-5529874-A | ETHER CARRIER LIQUID AND TONER PARTICLES DISPERSED THEREIN; SUITABLE FOR HIGH SPEED COPYING | FUJI XEROX CO., LTD. (JP) | 1996-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | DRD2 297/4885DRD4 1048/4885DRD3 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.